SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
